Renan Ozyerli, MD, MSD Turkey
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
MSD entered the Turkish pharma market in 1989 and established a subsidiary in 1993.
The headquarters are based in Istanbul. MSD employs 463 people in Human Health, as well as 32 people in Animal Health. Products are sourced from the global MSD network and toll manufacturing from 4 local companies. The subsidiary has a fully operational warehouse.
Currently, MSD Turkey is participating in 23 international clinical trials at 113 study centers. As such, the affiliate ranks among the top 3 research-based pharma companies in terms of clinical research capability. MSD Turkey also houses the management oversight/responsibility of Middle East and Egypt with 6 trials and 21 study centers in 5 different countries. In 2014, Merck HQ funded TRY 20.7 million (USD 9.5 million) to Turkey for clinical trials.
Contact Details
Merck Sharp Dohme İlaçları Ltd. Şti.
Esentepe Mah. Büyükdere Cad. No: 199
Levent 199 Ofis Bloğu Kat: 13, 34394 Levent-İstanbul
Tel:+90 212 336 1000
Fax:+90 212 215 2733
http://www.msd.com.tr/
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy…
Gilles Renacco, the recently appointed general manager of Servier Turkey, provides insights into the successful localization process pioneered by Servier in the country, where 98 percent of the company’s products…
Christopher Gaunt, chairman of the British Chamber of Commerce in Turkey, analyzes the relationship between the two countries and the ongoing development of their relationship, in addition to how UK…
Bahadir Kaleagasi, secretary general of the Turkish Industry & Business Association (TÜSIAD) discusses the strengths of the country as Europe’s gateway to Asia in addition to the strong investment landscape…
Murat Üçer, reputed macroeconomist, former advisor to the Ministry of Economy, Global Source Partners’ consultant in Turkey, co-founder of Turkey Data Monitor, and senior lecturer at Koç University, dissects the…
Dr. Uğur Baran, general secretary of OHSAD – Turkey’s Private Hospital and Health Organizations Association – highlights how he is striving to keep open the dialogue between the association and…
Dr. Ümit Dereli and Cengiz Aydın of the Association of Research-Based Pharmaceutical Companies (AIFD) inTurkey discuss significant recent changes in the Turkish ecosystem, including the improving recognition of the country’s regulatory…
Below is a list of the Top 100 Pharma Companies in Turkey sorted by the total value of sales in USD for 2014. Global giant Novartis is number one in…
Despite a current lack of investment incentives; Turkey’s geographical location, market size, large and aging population, universal healthcare, potential future spending, and stage of economic development mean that it is…
Although the Turkish pharmaceutical market has grown significantly in recent years R&D investment remains comparatively low. However, the expertise and capabilities exist for growth in this sector. Turkish companies and…
In the first fifteen years of the 21st century Turkey saw rapid economic growth, greater access to healthcare, and a boom in pharmaceutical sales. The country’s healthcare sector is now…
Tugce Gozacan (pictured) and Okan Gozacan, Owner and Chairman of Marmara Ecza respectively, discuss what qualities are crucial for suppliers in the pharmaceutical industry, their process for forming partnerships and…
The general manager of Drogsan, Ersan Kuçuk elaborates on the company’s efforts in shifting towards more value-added pharmaceutical products, specifically within the realm of biosimilars, while highlighting his ambitions in…
See our Cookie Privacy Policy Here